title: Selegiline transdermal system (STS) as an aid for smoking cessation.
abstract: BACKGROUND
  This study examined the efficacy and safety of selegiline transdermal system (STS) and brief repeated behavioral intervention (BRBI) for smoking cessation in heavy smokers. We hypothesized that the quit rate of subjects who received STS and BRBI would be significantly greater than that of those who received placebo patch and BRBI.
  
  
  METHODS
  This was a double-blind, placebo-controlled parallel-group study in which 246 men and women were randomized to receive either STS (n = 121) or placebo patch (n =125) for 9 weeks. Recruitment targeted heavy smokers, defined as individuals with self-reported use of ≥15 cigarettes/day in the 30 days prior to enrollment, who had smoked cigarettes for the past 5 years, and had an expired CO level ≥9 ppm during screening.
  
  
  RESULTS
  Although STS was well tolerated, the overall results indicated that STS with BRBI was not more effective than placebo plus BRBI for smoking cessation (p = .58).
  
  
  CONCLUSIONS
  The results are discussed in relation to interventions for heavy smokers. Although 2 trials using oral selegiline both showed trends toward improved abstinence, these results indicate that STS with BRBI was not an effective aid for smoking cessation at the end of treatment (10 weeks), 14, or 26 weeks.
authors.affiliation: Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, Bethesda, MD 20892, USA. rkan@nida.nih.gov
authors.forename: Roberta
authors.initials: R
authors.lastname: Kahn
authors.forename: Liza
authors.initials: L
authors.lastname: Gorgon
authors.forename: Karen
authors.initials: K
authors.lastname: Jones
authors.forename: Frances
authors.initials: F
authors.lastname: McSherry
authors.forename: Elbert D
authors.initials: ED
authors.lastname: Glover
authors.forename: Robert M
authors.initials: RM
authors.lastname: Anthenelli
authors.forename: Thomas
authors.initials: T
authors.lastname: Jackson
authors.forename: Jill
authors.initials: J
authors.lastname: Williams
authors.forename: Cristin
authors.initials: C
authors.lastname: Murtaugh
authors.forename: Ivan
authors.initials: I
authors.lastname: Montoya
authors.forename: Elmer
authors.initials: E
authors.lastname: Yu
authors.forename: Ahmed
authors.initials: A
authors.lastname: Elkashef
mesh_terms: D000279:Administration, Cutaneous; D000328:Adult; D001521:Behavior Therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D012642:Selegiline / Q000008:administration & dosage* / Q000627:therapeutic use*; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation / Q000379:methods*
chemical_list: D012642:Selegiline